ArticleLeukemia2026
A velocity-informed framework for resolving functional stratification in rare human stem cells.
Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell transcriptomics has transformed our understanding of stem cell biology; however, the analysis of extremely rare and quiescent populations remains limited by the low cell numbers and functional inaccessibility. Here, we present a velocity-informed framework to resolve transcriptional stratification in ultra-rare stem cells, using very small embryonic-like stem cells (VSELs) from human umbilical cord blood as a proof-of-concept model. By integrating single-cell RNA sequencing with dynamical RNA velocity analysis, we identify two kinetically distinct VSEL subsets: a CD34⁺ fraction characterized by deep quiescence, and a CD133⁺ fraction exhibiting transcriptional priming toward lineage commitment. Pathway-level analyses further reveal state-specific programs of stress response, metabolic regulation, and developmental gene networks. Importantly, our approach highlights how kinetic modeling can uncover functional continua even in populations not amenable to conventional assays. This framework is broadly applicable to rare or controversial stem cell types, providing a generalizable strategy to dissect cellular heterogeneity and state transitions where direct functional validation is constrained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.